ExploreWatchlistsPricing
  1. JP-listed companies
  3. Financials
  4. Operating expenses

(4597)

Market cap
¥9.6B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating expenses (Million JPY)YoY (%)
Dec 31, 2025637-62.99%
Dec 31, 20241,721+60.39%
Dec 31, 20231,073-52.31%
Dec 31, 20222,250+15.50%
Dec 31, 20211,948-19.90%
Dec 31, 20202,432+30.19%
Dec 31, 20191,868-27.62%
Dec 31, 20182,581+33.58%
Dec 31, 20171,932+29.48%
Dec 31, 20161,492-2.83%
Dec 31, 20151,536

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat